<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3854">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590547</url>
  </required_header>
  <id_info>
    <org_study_id>GLS27-005</org_study_id>
    <nct_id>NCT04590547</nct_id>
  </id_info>
  <brief_title>GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)</brief_title>
  <official_title>Safety, Tolerability and Efficacy of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneOne Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GeneOne Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the&#xD;
      prevention of severe pneumonitis caused by SARS-CoV-2 infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II randomized, double-blind, placebo-controlled, study will assess 2 different&#xD;
      doses of GLS-1027 in the prevention of severe pneumonitis among those hospitalized with PCR&#xD;
      confirmed SARS-CoV-2 infection. Subjects will be randomized at a 1:1:1 ratio to either&#xD;
      Standard of Care (SOC) plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily.&#xD;
      Clinical status will be monitored through 56 days from the initiation of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious adverse events relative to treatment group</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of progression to WHO Classification of ≥6 to include intubation with mechanical ventilation, need for ECMO, or death relative to treatment group</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days requiring ICU care relative to treatment group</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the number of days of mechanical ventilation relative to treatment group</measure>
    <time_frame>56 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Pneumonitis</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>GLS-1027 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 120 mg pill of GLS-1027 + 2 Placebo pills given by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLS-1027 360 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 120 mg pills of GLS-1027 given by mouth once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three Placebo pills given by mouth once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLS-1027</intervention_name>
    <description>GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.</description>
    <arm_group_label>GLS-1027 120 mg</arm_group_label>
    <arm_group_label>GLS-1027 360 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo looks like GLS-1027</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
          -  Able and willing to comply with study procedures&#xD;
&#xD;
          -  Enrollment within 72 of hospitalization with a diagnosis of PCR confirmed SARS-CoV-2&#xD;
&#xD;
          -  WHO COVID-19 classification level 3 or 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  SpO2 less than 90% on room air&#xD;
&#xD;
          -  Calculated GFR &lt; 60 (Cockcroft-Gault)&#xD;
&#xD;
          -  Meets treatment algorithm criteria for treatment with toclizumab or other anti-IL-6&#xD;
             agent&#xD;
&#xD;
          -  Treatment with an anti-IL-6 inhibitor, anti-IL-1 inhibitor, anti-TNF monoclonal&#xD;
             antibody, or anti-JAK inhibitor&#xD;
&#xD;
          -  Participation in a COVID-19 clinical trial that includes prescription of a drug with&#xD;
             anti-cytokine activity&#xD;
&#xD;
          -  Treatment within the past 60 days with a chemotherapeutic agent&#xD;
&#xD;
          -  Current treatment with systemic corticosteroids at a dose equivalent of 20 mg/day or&#xD;
             greater of prednisone or prednisolone or 16 mg/day or greater of methylprednisolone&#xD;
&#xD;
          -  Diagnosis of leukemia or lymphoma&#xD;
&#xD;
          -  WHO COVID-19 classification level of 5 or greater (use of high-flow oxygen,&#xD;
             non-mechanical ventilation such as CPAP, mechanical ventilation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>484-965-9147</phone>
    <email>jmaslow@geneonels-us.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Project Manager</last_name>
    <email>cremigio@geneonels-us.com</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

